Behcet's Disease

Autoimmune MONDO:0007191 Pathograph 13 Show in embeddings browser Autoimmune Disease Vasculitis

A systemic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Involves both arterial and venous vessels of all sizes. Highly prevalent along the ancient Silk Road. Classified as a variable vessel vasculitis with autoinflammatory features.

Ask OpenScientist

Ask a research question about Behcet's Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Pathophys.
24
Phenotypes
13
Pathograph
3
Genes
5
Medical Actions
6
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
IMMUNE_RHEUMATOLOGIC
⚙

Pathophysiology

3
HLA-B51-Associated Immune Dysregulation
Strong association with HLA-B51. Aberrant peptide presentation and cross-reactivity with microbial antigens may trigger autoinflammatory responses. ERAP1 variants affect peptide processing for HLA-B51.
Antigen Presentation GO:0019882
Downstream
Neutrophil Hyperactivation HLA-B51-associated immune dysregulation is modeled upstream of the innate neutrophil hyperactivation branch in Behcet disease.
Th1/Th17 Cytokine Imbalance HLA-B51-associated immune dysregulation is modeled upstream of adaptive Th1/Th17 cytokine imbalance in Behcet disease.
Show evidence (1 reference)
PMID:38778397 PARTIAL
"genetic factors (such as HLA-B51), dysregulated immune responses of both the innate and adaptive immune systems, infections (such as streptococcus), and environmental factors (such as GDP) are all involved in its development."
This review confirms that HLA-B51 is a key genetic factor in Behcet's disease pathogenesis, supporting the role of aberrant antigen presentation in disease development.
Neutrophil Hyperactivation
Neutrophils show enhanced chemotaxis, phagocytosis, and oxidative burst. Pathergy response (exaggerated skin reaction to minor trauma) reflects neutrophil hyperreactivity. NETs may contribute to vascular damage.
Neutrophil CL:0000775
Neutrophil Activation GO:0042119
Downstream
Oral Ulcers Neutrophil-dominant innate inflammation contributes to mucocutaneous ulceration in Behcet disease.
Genital Ulcers Neutrophil-dominant innate inflammation contributes to genital aphthous ulceration in Behcet disease.
Skin Lesions Neutrophilic dermatitis and panniculitis provide the inflammatory substrate for Behcet skin lesions.
Erythema Nodosum Erythema nodosum is part of the neutrophil-rich inflammatory skin phenotype in Behcet disease.
Pustule Pustular skin lesions and positive pathergy reflect exaggerated innate inflammatory responses to minor skin injury.
Positive Pathergy Test The pathergy response is modeled as a clinical readout of neutrophil hyperreactivity after minor trauma.
Show evidence (2 references)
PMID:38778397 PARTIAL
"Innate immunity, including hyperactivity of neutrophils and γδT cells and elevated NK1/NK2 ratios, has been shown to play an essential role in this disease."
This review highlights neutrophil hyperactivity as a key feature of innate immune dysregulation in Behcet's uveitis, supporting the role of neutrophil activation in pathogenesis.
PMID:37435539 SUPPORT
"Skin histopathology demonstrates the overactivation of innate immunity, such as neutrophilic dermatitis/panniculitis, in patients with BD."
Histopathological evidence confirms neutrophil overactivation in Behcet's disease skin lesions, demonstrating the pathologic role of neutrophils in tissue inflammation.
Th1/Th17 Cytokine Imbalance
Elevated IL-17, IFN-gamma, and TNF-alpha drive tissue inflammation. IL-23/IL-17 axis is particularly important and represents a therapeutic target.
T Helper Cell CL:0000492
Inflammatory Response GO:0006954
Downstream
Uveitis Th1/Th17 overactivation is modeled as a driver of Behcet uveitis.
Arthritis Systemic Th1/Th17 cytokine imbalance contributes to inflammatory joint manifestations.
Vasculitis Systemic cytokine imbalance contributes to Behcet variable-vessel vasculitis.
Venous Thrombosis Vascular inflammation in Behcet disease can manifest as venous thrombosis.
Show evidence (1 reference)
PMID:38778397 SUPPORT
"Adaptive immune system disturbance, including homeostatic perturbations, Th1, Th17 overaction, and Treg cell dysfunction, is thought to be involved in BU pathogenesis."
This review describes the imbalance between pro-inflammatory Th1/Th17 responses and regulatory T cell dysfunction as central to Behcet's uveitis pathogenesis, supporting the role of cytokine imbalance in disease progression.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Behcet's Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

24
Cardiovascular 1
Vasculitis VERY_FREQUENT Vasculitis HP:0002633
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0002633 | Vasculitis | Very frequent (99-80%)"
Orphanet records vasculitis as a very frequent (80-99%) phenotype of Behçet disease.
Digestive 1
Nausea and vomiting VERY_FREQUENT Nausea and vomiting HP:0002017
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0002017 | Nausea and vomiting | Very frequent (99-80%)"
Orphanet records nausea and vomiting as a very frequent (80-99%) phenotype of Behçet disease.
Eye 2
Uveitis FREQUENT Uveitis HP:0000554
Panuveitis, may cause blindness
Show evidence (1 reference)
PMID:38778397 SUPPORT
"Behcet's uveitis (BU) is a common manifestation of BD, occurring in over two-thirds of the patients. BU is characterized by bilateral, chronic, recurrent, non-granulomatous uveitis in association with complications such as retinal ischemia and atrophy, optic atrophy, macular ischemia, macular..."
This review confirms that uveitis occurs in over two-thirds of Behcet's disease patients and describes its bilateral, recurrent nature and sight-threatening complications including potential blindness.
Photophobia VERY_FREQUENT Photophobia HP:0000613
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0000613 | Photophobia | Very frequent (99-80%)"
Orphanet records photophobia as a very frequent (80-99%) phenotype of Behçet disease.
Genitourinary 1
Genital Ulcers FREQUENT Genital ulcers HP:0003249
Often scarring
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0003249 | Genital ulcers | Frequent (79-30%)"
Orphanet records genital ulcers as a frequent phenotype of Behcet disease.
Head and Neck 1
Oral Ulcers VERY_FREQUENT Oral ulcer HP:0000155
Recurrent, painful aphthous ulcers
Show evidence (1 reference)
PMID:37435539 SUPPORT
"Major clinical manifestations of BD are oral aphthae, genital aphthous ulcers, skin lesions, arthritis, and uveitis."
Oral aphthae are listed as a major clinical manifestation of Behcet's disease, confirming their central role in diagnosis.
Immune 5
Skin Lesions FREQUENT Skin rash HP:0000988
Erythema nodosum, pseudofolliculitis
Show evidence (1 reference)
PMID:37435539 SUPPORT Human Clinical
"Major clinical manifestations of BD are oral aphthae, genital aphthous ulcers, skin lesions, arthritis, and uveitis."
Skin lesions are listed among the major clinical manifestations of Behcet disease.
Erythema Nodosum FREQUENT Erythema nodosum HP:0012219
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0012219 | Erythema nodosum | Frequent (79-30%)"
Orphanet records erythema nodosum as a frequent phenotype of Behçet disease.
Pustule FREQUENT Pustule HP:0200039
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0200039 | Pustule | Frequent (79-30%)"
Orphanet records pustule as a frequent phenotype of Behçet disease.
Meningitis OCCASIONAL Meningitis HP:0001287
Show evidence (1 reference)
PMID:23830180 SUPPORT Human Clinical
"Neurological involvement was observed in 121 patients (28.1%)."
In a retrospective cohort of 430 Behçet disease patients, neuro-Behçet (which encompasses meningitis/meningoencephalitis) affected 28.1% — a minority. Meningitis is a subset of this, so it falls well below the Orphanet "very frequent (80-99%)" band, supporting an OCCASIONAL primary frequency.
Context-specific annotations (1)
VERY_FREQUENT
Source-specific assertion from the Orphanet product4 dataset, which assigns a higher frequency band than clinical cohorts. Retained for provenance; the primary frequency above reflects clinical-literature estimates.
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001287 | Meningitis | Very frequent (99-80%)"
Orphanet records meningitis as a very frequent (80-99%) phenotype of Behçet disease.
Acne FREQUENT Acne HP:0001061
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001061 | Acne | Frequent (79-30%)"
Orphanet records acne as a frequent (30-79%) phenotype of Behçet disease.
Integument 1
Subcutaneous nodule VERY_FREQUENT Subcutaneous nodule HP:0001482
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001482 | Subcutaneous nodule | Very frequent (99-80%)"
Orphanet records subcutaneous nodule as a very frequent (80-99%) phenotype of Behçet disease.
Metabolism 1
Fever VERY_FREQUENT Fever HP:0001945
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001945 | Fever | Very frequent (99-80%)"
Orphanet records fever as a very frequent (80-99%) phenotype of Behçet disease.
Musculoskeletal 1
Arthritis VERY_FREQUENT Arthritis HP:0001369
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001369 | Arthritis | Very frequent (99-80%)"
Orphanet records arthritis as a very frequent (80-99%) phenotype of Behçet disease.
Nervous System 3
Migraine VERY_FREQUENT Migraine HP:0002076
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0002076 | Migraine | Very frequent (99-80%)"
Orphanet records migraine as a very frequent (80-99%) phenotype of Behçet disease.
Hemiparesis FREQUENT Hemiparesis HP:0001269
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001269 | Hemiparesis | Frequent (79-30%)"
Orphanet records hemiparesis as a frequent (30-79%) phenotype of Behçet disease.
Gait disturbance FREQUENT Gait disturbance HP:0001288
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0001288 | Gait disturbance | Frequent (79-30%)"
Orphanet records gait disturbance as a frequent (30-79%) phenotype of Behçet disease.
Constitutional 2
Myalgia VERY_FREQUENT Myalgia HP:0003326
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0003326 | Myalgia | Very frequent (99-80%)"
Orphanet records myalgia as a very frequent (80-99%) phenotype of Behçet disease.
Fatigue VERY_FREQUENT Fatigue HP:0012378
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0012378 | Fatigue | Very frequent (99-80%)"
Orphanet records fatigue as a very frequent (80-99%) phenotype of Behçet disease.
Other 5
Positive Pathergy Test FREQUENT Positive pathergy test HP:0025532
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0025532 | Positive pathergy test | Frequent (79-30%)"
Orphanet records positive pathergy test as a frequent phenotype of Behçet disease.
Venous Thrombosis FREQUENT Venous thrombosis HP:0004936
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0004936 | Venous thrombosis | Frequent (79-30%)"
Orphanet records venous thrombosis as a frequent phenotype of Behçet disease.
Recurrent aphthous stomatitis VERY_FREQUENT Recurrent aphthous stomatitis HP:0011107
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0011107 | Recurrent aphthous stomatitis | Very frequent (99-80%)"
Orphanet records recurrent aphthous stomatitis as a very frequent (80-99%) phenotype of Behçet disease.
Orchitis OCCASIONAL Orchitis HP:0100796
Show evidence (1 reference)
PMID:29998839 SUPPORT Human Clinical
"epididymo-orchitis: 8.7% (boys)"
In a cohort of 204 paediatric Behçet disease patients, epididymo-orchitis occurred in 8.7% of boys — far below the Orphanet "very frequent (80-99%)" band and consistent with the ~5-12% reported in adult male cohorts; supports an OCCASIONAL primary frequency.
Context-specific annotations (1)
VERY_FREQUENT
Source-specific assertion from the Orphanet product4 dataset, which assigns a higher frequency band than clinical cohorts. Retained for provenance; the primary frequency above reflects clinical-literature estimates.
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0100796 | Orchitis | Very frequent (99-80%)"
Orphanet records orchitis as a very frequent (80-99%) phenotype of Behçet disease.
Papule VERY_FREQUENT Papule HP:0200034
Show evidence (1 reference)
ORPHA:117 SUPPORT Other
"HP:0200034 | Papule | Very frequent (99-80%)"
Orphanet records papule as a very frequent (80-99%) phenotype of Behçet disease.
🧬

Genetic Associations

3
HLA-B51 (Strong Risk Factor)
ERAP1 (Risk Factor)
IL10 (Risk Factor)
💊

Medical Actions

5
Colchicine
For mucocutaneous manifestations.
Corticosteroids
For acute flares and severe manifestations.
Azathioprine
For maintenance and uveitis.
TNF Inhibitors
For refractory disease, especially uveitis.
Apremilast
For oral ulcers.
🔬

Biochemical Markers

2
ESR (Elevated)
Context: During active disease
CRP (Elevated)
Context: Inflammation marker
{ }

Source YAML

click to show 
name: Behcet's Disease
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-02-17T21:53:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Vasculitis
disease_term:
  preferred_term: Behcet Disease
  term:
    id: MONDO:0007191
    label: Behcet disease
description: >-
  A systemic inflammatory disorder characterized by recurrent oral and genital
  ulcers, uveitis, and skin lesions. Involves both arterial and venous vessels
  of all sizes. Highly prevalent along the ancient Silk Road. Classified as a
  variable vessel vasculitis with autoinflammatory features.
pathophysiology:
- name: HLA-B51-Associated Immune Dysregulation
  description: >-
    Strong association with HLA-B51. Aberrant peptide presentation and
    cross-reactivity with microbial antigens may trigger autoinflammatory
    responses. ERAP1 variants affect peptide processing for HLA-B51.
  biological_processes:
  - preferred_term: Antigen Presentation
    term:
      id: GO:0019882
      label: antigen processing and presentation
  evidence:
  - reference: PMID:38778397
    reference_title: "Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances."
    supports: PARTIAL
    snippet: >-
      genetic factors (such as HLA-B51), dysregulated immune responses of both
      the innate and adaptive immune systems, infections (such as streptococcus),
      and environmental factors (such as GDP) are all involved in its development.
    explanation: >-
      This review confirms that HLA-B51 is a key genetic factor in Behcet's
      disease pathogenesis, supporting the role of aberrant antigen presentation
      in disease development.
  downstream:
  - target: Neutrophil Hyperactivation
    description: >-
      HLA-B51-associated immune dysregulation is modeled upstream of the innate
      neutrophil hyperactivation branch in Behcet disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Th1/Th17 Cytokine Imbalance
    description: >-
      HLA-B51-associated immune dysregulation is modeled upstream of adaptive
      Th1/Th17 cytokine imbalance in Behcet disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Neutrophil Hyperactivation
  description: >-
    Neutrophils show enhanced chemotaxis, phagocytosis, and oxidative burst.
    Pathergy response (exaggerated skin reaction to minor trauma) reflects
    neutrophil hyperreactivity. NETs may contribute to vascular damage.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: Neutrophil Activation
    term:
      id: GO:0042119
      label: neutrophil activation
  evidence:
  - reference: PMID:38778397
    reference_title: "Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances."
    supports: PARTIAL
    snippet: >-
      Innate immunity, including hyperactivity of neutrophils and γδT cells and
      elevated NK1/NK2 ratios, has been shown to play an essential role in this
      disease.
    explanation: >-
      This review highlights neutrophil hyperactivity as a key feature of
      innate immune dysregulation in Behcet's uveitis, supporting the role of
      neutrophil activation in pathogenesis.
  - reference: PMID:37435539
    reference_title: "Innate immune responses in Behçet disease and relapsing polychondritis."
    supports: SUPPORT
    snippet: >-
      Skin histopathology demonstrates the overactivation of innate immunity,
      such as neutrophilic dermatitis/panniculitis, in patients with BD.
    explanation: >-
      Histopathological evidence confirms neutrophil overactivation in Behcet's
      disease skin lesions, demonstrating the pathologic role of neutrophils in
      tissue inflammation.
  downstream:
  - target: Oral Ulcers
    description: >-
      Neutrophil-dominant innate inflammation contributes to mucocutaneous
      ulceration in Behcet disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Genital Ulcers
    description: >-
      Neutrophil-dominant innate inflammation contributes to genital aphthous
      ulceration in Behcet disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Skin Lesions
    description: >-
      Neutrophilic dermatitis and panniculitis provide the inflammatory
      substrate for Behcet skin lesions.
    causal_link_type: DIRECT
  - target: Erythema Nodosum
    description: >-
      Erythema nodosum is part of the neutrophil-rich inflammatory skin
      phenotype in Behcet disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Pustule
    description: >-
      Pustular skin lesions and positive pathergy reflect exaggerated innate
      inflammatory responses to minor skin injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Positive Pathergy Test
    description: >-
      The pathergy response is modeled as a clinical readout of neutrophil
      hyperreactivity after minor trauma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Th1/Th17 Cytokine Imbalance
  description: >-
    Elevated IL-17, IFN-gamma, and TNF-alpha drive tissue inflammation.
    IL-23/IL-17 axis is particularly important and represents a therapeutic
    target.
  cell_types:
  - preferred_term: T Helper Cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:38778397
    reference_title: "Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances."
    supports: SUPPORT
    snippet: >-
      Adaptive immune system disturbance, including homeostatic perturbations,
      Th1, Th17 overaction, and Treg cell dysfunction, is thought to be involved
      in BU pathogenesis.
    explanation: >-
      This review describes the imbalance between pro-inflammatory Th1/Th17
      responses and regulatory T cell dysfunction as central to Behcet's uveitis
      pathogenesis, supporting the role of cytokine imbalance in disease
      progression.
  downstream:
  - target: Uveitis
    description: >-
      Th1/Th17 overactivation is modeled as a driver of Behcet uveitis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Arthritis
    description: >-
      Systemic Th1/Th17 cytokine imbalance contributes to inflammatory joint
      manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Vasculitis
    description: >-
      Systemic cytokine imbalance contributes to Behcet variable-vessel
      vasculitis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Venous Thrombosis
    description: >-
      Vascular inflammation in Behcet disease can manifest as venous
      thrombosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- name: Oral Ulcers
  category: Oral
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Oral Ulcer
    term:
      id: HP:0000155
      label: Oral ulcer
  notes: Recurrent, painful aphthous ulcers
  evidence:
  - reference: PMID:37435539
    reference_title: "Innate immune responses in Behçet disease and relapsing polychondritis."
    supports: SUPPORT
    snippet: >-
      Major clinical manifestations of BD are oral aphthae, genital aphthous
      ulcers, skin lesions, arthritis, and uveitis.
    explanation: >-
      Oral aphthae are listed as a major clinical manifestation of Behcet's
      disease, confirming their central role in diagnosis.
- name: Genital Ulcers
  category: Genitourinary
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Genital ulcers
    term:
      id: HP:0003249
      label: Genital ulcers
  notes: Often scarring
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003249 | Genital ulcers | Frequent (79-30%)"
    explanation: Orphanet records genital ulcers as a frequent phenotype of Behcet disease.
- name: Uveitis
  category: Ophthalmological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Uveitis
    term:
      id: HP:0000554
      label: Uveitis
  notes: Panuveitis, may cause blindness
  evidence:
  - reference: PMID:38778397
    reference_title: "Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances."
    supports: SUPPORT
    snippet: >-
      Behcet's uveitis (BU) is a common manifestation of BD, occurring in over
      two-thirds of the patients. BU is characterized by bilateral, chronic,
      recurrent, non-granulomatous uveitis in association with complications
      such as retinal ischemia and atrophy, optic atrophy, macular ischemia,
      macular edema, and further neovascular complications (vitreous hemorrhage,
      neovascular glaucoma).
    explanation: >-
      This review confirms that uveitis occurs in over two-thirds of Behcet's
      disease patients and describes its bilateral, recurrent nature and
      sight-threatening complications including potential blindness.
- name: Skin Lesions
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Skin Rash
    term:
      id: HP:0000988
      label: Skin rash
  notes: Erythema nodosum, pseudofolliculitis
  evidence:
  - reference: PMID:37435539
    reference_title: "Innate immune responses in Behçet disease and relapsing polychondritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Major clinical manifestations of BD are oral aphthae, genital aphthous
      ulcers, skin lesions, arthritis, and uveitis.
    explanation: >-
      Skin lesions are listed among the major clinical manifestations of Behcet
      disease.
- name: "Erythema Nodosum"
  category: Dermatologic
  frequency: FREQUENT
  description: "Erythema nodosum is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Erythema nodosum"
    term:
      id: HP:0012219
      label: "Erythema nodosum"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012219 | Erythema nodosum | Frequent (79-30%)"
    explanation: "Orphanet records erythema nodosum as a frequent phenotype of Behçet disease."
- name: "Pustule"
  category: Dermatologic
  frequency: FREQUENT
  description: "Pustules are reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Pustule"
    term:
      id: HP:0200039
      label: "Pustule"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200039 | Pustule | Frequent (79-30%)"
    explanation: "Orphanet records pustule as a frequent phenotype of Behçet disease."
- name: "Positive Pathergy Test"
  category: Dermatologic
  frequency: FREQUENT
  description: "Positive pathergy test is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Positive pathergy test"
    term:
      id: HP:0025532
      label: "Positive pathergy test"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025532 | Positive pathergy test | Frequent (79-30%)"
    explanation: "Orphanet records positive pathergy test as a frequent phenotype of Behçet disease."
- name: "Venous Thrombosis"
  category: Cardiovascular
  frequency: FREQUENT
  description: "Venous thrombosis is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Venous thrombosis"
    term:
      id: HP:0004936
      label: "Venous thrombosis"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004936 | Venous thrombosis | Frequent (79-30%)"
    explanation: "Orphanet records venous thrombosis as a frequent phenotype of Behçet disease."
- name: "Photophobia"
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  description: "Photophobia is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Photophobia"
    term:
      id: HP:0000613
      label: "Photophobia"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000613 | Photophobia | Very frequent (99-80%)"
    explanation: "Orphanet records photophobia as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Meningitis"
  category: Neurologic
  frequency: OCCASIONAL
  description: >-
    Aseptic meningitis/meningoencephalitis occurs as part of neuro-Behçet
    disease. The Orphanet product4 dataset assigns a "very frequent" band, but
    clinical cohorts place overall neurological involvement at roughly 18-28%,
    with isolated meningitis a smaller subset. The primary OCCASIONAL band
    reflects the clinical literature; the Orphanet band is retained below as a
    source-specific context.
  phenotype_term:
    preferred_term: "Meningitis"
    term:
      id: HP:0001287
      label: "Meningitis"
  evidence:
  - reference: PMID:23830180
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological involvement was observed in 121 patients (28.1%)."
    explanation: >-
      In a retrospective cohort of 430 Behçet disease patients, neuro-Behçet
      (which encompasses meningitis/meningoencephalitis) affected 28.1% — a
      minority. Meningitis is a subset of this, so it falls well below the
      Orphanet "very frequent (80-99%)" band, supporting an OCCASIONAL primary
      frequency.
  phenotype_contexts:
  - frequency: VERY_FREQUENT
    notes: >-
      Source-specific assertion from the Orphanet product4 dataset, which
      assigns a higher frequency band than clinical cohorts. Retained for
      provenance; the primary frequency above reflects clinical-literature
      estimates.
    evidence:
    - reference: ORPHA:117
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001287 | Meningitis | Very frequent (99-80%)"
      explanation: "Orphanet records meningitis as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Arthritis"
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: "Arthritis is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Arthritis"
    term:
      id: HP:0001369
      label: "Arthritis"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001369 | Arthritis | Very frequent (99-80%)"
    explanation: "Orphanet records arthritis as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Subcutaneous nodule"
  category: Dermatologic
  frequency: VERY_FREQUENT
  description: "Subcutaneous nodule is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Subcutaneous nodule"
    term:
      id: HP:0001482
      label: "Subcutaneous nodule"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001482 | Subcutaneous nodule | Very frequent (99-80%)"
    explanation: "Orphanet records subcutaneous nodule as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Fever"
  category: Constitutional
  frequency: VERY_FREQUENT
  description: "Fever is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Fever"
    term:
      id: HP:0001945
      label: "Fever"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001945 | Fever | Very frequent (99-80%)"
    explanation: "Orphanet records fever as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Nausea and vomiting"
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  description: "Nausea and vomiting is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Nausea and vomiting"
    term:
      id: HP:0002017
      label: "Nausea and vomiting"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002017 | Nausea and vomiting | Very frequent (99-80%)"
    explanation: "Orphanet records nausea and vomiting as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Migraine"
  category: Neurologic
  frequency: VERY_FREQUENT
  description: "Migraine is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Migraine"
    term:
      id: HP:0002076
      label: "Migraine"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002076 | Migraine | Very frequent (99-80%)"
    explanation: "Orphanet records migraine as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Vasculitis"
  category: Cardiovascular
  frequency: VERY_FREQUENT
  description: "Vasculitis is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Vasculitis"
    term:
      id: HP:0002633
      label: "Vasculitis"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002633 | Vasculitis | Very frequent (99-80%)"
    explanation: "Orphanet records vasculitis as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Myalgia"
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: "Myalgia is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Myalgia"
    term:
      id: HP:0003326
      label: "Myalgia"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003326 | Myalgia | Very frequent (99-80%)"
    explanation: "Orphanet records myalgia as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Recurrent aphthous stomatitis"
  category: Dermatologic
  frequency: VERY_FREQUENT
  description: "Recurrent aphthous stomatitis is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Recurrent aphthous stomatitis"
    term:
      id: HP:0011107
      label: "Recurrent aphthous stomatitis"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011107 | Recurrent aphthous stomatitis | Very frequent (99-80%)"
    explanation: "Orphanet records recurrent aphthous stomatitis as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Fatigue"
  category: Constitutional
  frequency: VERY_FREQUENT
  description: "Fatigue is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Fatigue"
    term:
      id: HP:0012378
      label: "Fatigue"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
    explanation: "Orphanet records fatigue as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Orchitis"
  category: Genitourinary
  frequency: OCCASIONAL
  description: >-
    Epididymo-orchitis is a recognized but uncommon manifestation of Behçet
    disease in males. The Orphanet product4 dataset assigns a "very frequent"
    band, but clinical cohorts report it in roughly 5-12% of male patients. The
    primary OCCASIONAL band reflects the clinical literature; the Orphanet band
    is retained below as a source-specific context.
  phenotype_term:
    preferred_term: "Orchitis"
    term:
      id: HP:0100796
      label: "Orchitis"
  evidence:
  - reference: PMID:29998839
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "epididymo-orchitis: 8.7% (boys)"
    explanation: >-
      In a cohort of 204 paediatric Behçet disease patients, epididymo-orchitis
      occurred in 8.7% of boys — far below the Orphanet "very frequent (80-99%)"
      band and consistent with the ~5-12% reported in adult male cohorts;
      supports an OCCASIONAL primary frequency.
  phenotype_contexts:
  - frequency: VERY_FREQUENT
    notes: >-
      Source-specific assertion from the Orphanet product4 dataset, which
      assigns a higher frequency band than clinical cohorts. Retained for
      provenance; the primary frequency above reflects clinical-literature
      estimates.
    evidence:
    - reference: ORPHA:117
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0100796 | Orchitis | Very frequent (99-80%)"
      explanation: "Orphanet records orchitis as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Papule"
  category: Dermatologic
  frequency: VERY_FREQUENT
  description: "Papule is reported as a very frequent (80-99%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Papule"
    term:
      id: HP:0200034
      label: "Papule"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200034 | Papule | Very frequent (99-80%)"
    explanation: "Orphanet records papule as a very frequent (80-99%) phenotype of Behçet disease."
- name: "Acne"
  category: Dermatologic
  frequency: FREQUENT
  description: "Acne is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Acne"
    term:
      id: HP:0001061
      label: "Acne"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001061 | Acne | Frequent (79-30%)"
    explanation: "Orphanet records acne as a frequent (30-79%) phenotype of Behçet disease."
- name: "Hemiparesis"
  category: Neurologic
  frequency: FREQUENT
  description: "Hemiparesis is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Hemiparesis"
    term:
      id: HP:0001269
      label: "Hemiparesis"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001269 | Hemiparesis | Frequent (79-30%)"
    explanation: "Orphanet records hemiparesis as a frequent (30-79%) phenotype of Behçet disease."
- name: "Gait disturbance"
  category: Neurologic
  frequency: FREQUENT
  description: "Gait disturbance is reported as a frequent (30-79%) manifestation of Behçet disease in the Orphanet clinical phenotype dataset."
  phenotype_term:
    preferred_term: "Gait disturbance"
    term:
      id: HP:0001288
      label: "Gait disturbance"
  evidence:
  - reference: ORPHA:117
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: "Orphanet records gait disturbance as a frequent (30-79%) phenotype of Behçet disease."
biochemical:
- name: ESR
  presence: Elevated
  context: During active disease
- name: CRP
  presence: Elevated
  context: Inflammation marker
genetic:
- name: HLA-B51
  association: Strong Risk Factor
  notes: Present in 60-70% of patients from endemic regions
- name: ERAP1
  association: Risk Factor
- name: IL10
  association: Risk Factor
treatments:
- name: Colchicine
  description: For mucocutaneous manifestations.
- name: Corticosteroids
  description: For acute flares and severe manifestations.
- name: Azathioprine
  description: For maintenance and uveitis.
- name: TNF Inhibitors
  description: For refractory disease, especially uveitis.
- name: Apremilast
  description: For oral ulcers.
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
references:
- reference: DOI:10.1038/s41598-025-87130-4
  title: Integrated analysis of genetic, proteinic, and metabolomic alterations in Behcet’s disease
  findings: []
- reference: DOI:10.1056/nejmra2305712
  title: Behçet’s Syndrome
  findings: []
- reference: DOI:10.1186/s12974-024-03123-6
  title: 'Decoding Behcet’s Uveitis: an In-depth review of pathogenesis and therapeutic advances'
  findings: []
- reference: DOI:10.3389/fimmu.2023.1206959
  title: Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease
  findings: []
- reference: DOI:10.3389/fmed.2023.1055753
  title: Innate immune responses in Behçet disease and relapsing polychondritis
  findings: []
- reference: DOI:10.3390/medicina60040562
  title: 'Behçet’s Disease, Pathogenesis, Clinical Features, and Treatment Approaches: A Comprehensive Review'
  findings: []
📚

References & Deep Research

References

6
DOI:10.1038/s41598-025-87130-4
Integrated analysis of genetic, proteinic, and metabolomic alterations in Behcet’s disease
No top-level findings curated for this source.
DOI:10.1056/nejmra2305712
Behçet’s Syndrome
No top-level findings curated for this source.
DOI:10.1186/s12974-024-03123-6
Decoding Behcet’s Uveitis: an In-depth review of pathogenesis and therapeutic advances
No top-level findings curated for this source.
DOI:10.3389/fimmu.2023.1206959
Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease
No top-level findings curated for this source.
DOI:10.3389/fmed.2023.1055753
Innate immune responses in Behçet disease and relapsing polychondritis
No top-level findings curated for this source.
DOI:10.3390/medicina60040562
Behçet’s Disease, Pathogenesis, Clinical Features, and Treatment Approaches: A Comprehensive Review
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Behcet's Disease
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 12

Key Pathophysiology Nodes

  • HLA-B51-Associated Immune Dysregulation
  • Neutrophil Hyperactivation
  • Th1/Th17 Cytokine Imbalance
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1038/s41598-025-87130-4
  • DOI:10.1056/nejmra2305712
  • DOI:10.1186/s12974-024-03123-6
  • DOI:10.3389/fimmu.2023.1206959
  • DOI:10.3389/fmed.2023.1055753
  • DOI:10.3390/medicina60040562
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 22 citations 2025-12-18T09:53:57.515947

Disease Pathophysiology Research Report

Target Disease - Disease Name: Behçet’s Disease (BD) - MONDO ID:
- Category: Autoimmune/autoinflammatory variable-vessel vasculitis

Pathophysiology overview (current understanding, 2023–2024) Behçet’s disease is now regarded as a primary systemic vasculitis affecting veins and arteries of any size, driven by gene–environment interactions that dysregulate both innate and adaptive immunity. Core features include neutrophil hyperactivation and NET formation, Th1/Th17 polarization with impaired regulatory T-cell control, endothelial dysfunction and microthrombosis, and genetic risk dominated by HLA-B*51 with ERAP1 epistasis and non‑HLA loci linked to IL-23/Th17 and IL-10 pathways (IL23R–IL12RB2, STAT4, IL10, CCR1/KLRC4, MICA). Interferon/JAK–STAT and NF‑κB signaling in antigen-presenting cells contribute to systemic inflammation. Oral/gut microbial dysbiosis is plausibly involved as a trigger and amplifier of mucosal and ocular auto-inflammation. These mechanisms connect to major organ phenotypes: mucocutaneous ulcers, vision-threatening uveitis, vascular thrombosis/aneurysm, ileocecal intestinal disease, and neuro-Behçet (parenchymal and vascular forms) (https://doi.org/10.1056/NEJMra2305712; Feb 15, 2024) (saadoun2024behçetssyndrome. pages 1-2). Ocular reviews and integrated omics reinforce Th1/Th17 dominance and neutrophil/endothelial axes, with emerging targets in JAK–STAT and Th17/Treg balance (https://doi.org/10.1186/s12974-024-03123-6; May 2024; https://doi.org/10.3389/fimmu.2023.1206959; Sep 2023; https://doi.org/10.1038/s41598-025-87130-4; Jan 2025) (guan2024decodingbehcet’suveitis pages 1-2, lin2023advancesinpathogenesis pages 1-2, pu2025integratedanalysisof pages 8-9).

Evidence table | Mechanism / Theme | Key molecules / genes (HGNC) | Cell types (CL) | Organ / tissue (UBERON) | Representative finding (2023–2024, quantitative where available) | Therapeutic implication | Source | |---|---|---:|---|---|---|---| | Neutrophil hyperactivation & NETs | MPO, ELANE, PADI4 | Neutrophil (CL) | Blood, skin, oral mucosa (UBERON) | NET formation and neutrophil hyperactivation drive endothelial injury and a procoagulant state in BD; NETs linked to tissue vasculitis and mucosal damage (multiple 2023–2025 multi-omic/review reports). | Targeting innate neutrophil activation/NETs (anti-TNF, anti-IL‑1, DNase approaches) may reduce vasculitis and mucosal injury. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Shimizu J., Front Med/2023, https://doi.org/10.3389/fmed.2023.1055753 (shimizu2023innateimmuneresponses pages 10-11); Pu Y., Sci Rep/2025, https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9) | | Th1 / Th17 / Treg imbalance and Tc17 | IFNG, IL17A, IL23R, IL10, STAT4 | CD4+ Th1/Th17, CD8+ Tc17, Treg (CL) | Peripheral blood, mucosa, ocular tissues | Consistent Th1 (IFN-γ)/Th17 (IL‑17/IL‑23) skewing with reduced regulatory T‑cell control; multi‑omic data identify Th1/Th17 hyperactivity as dominant signature in BD (integrated analyses). | Cytokine-targeting (anti‑IL‑17, anti‑IL‑12/23), JAK inhibition and therapies restoring Treg/Th17 balance are rational strategies. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Pu Y., Sci Rep/2025, https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9); Guan Y., J Neuroinflamm/2024, https://doi.org/10.1186/s12974-024-03123-6 (guan2024decodingbehcet’suveitis pages 1-2) | | Endothelial dysfunction & vasculitis biology | ICAM1, SELE, prothrombotic mediators | Endothelial cell, platelets, neutrophils (CL) | Arterial & venous vessels (UBERON:vasculature) | Histology shows leukocytoclastic vasculitis, perivascular infiltrates and microthrombi; multi‑omics report endothelial injury and haemostatic activation as core features. | Anticytokine (anti‑TNF), anticoagulation considerations and therapies reducing endothelial activation are key; IL‑1/IL‑6 blockade considered in selected vascular BD. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Pu Y., Sci Rep/2025, https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9); Lavalle S., Medicina/2024, https://doi.org/10.3390/medicina60040562 (lavalle2024behçet’sdiseasepathogenesis pages 10-11) | | Genetics: HLA‑B51 – ERAP1, IL10, IL23R–IL12RB2, STAT4, CCR1/KLRC4, MICA | HLA‑B (HLA‑B51), ERAP1, IL10, IL23R, IL12RB2, STAT4, CCR1, KLRC4, MICA | Antigen‑presenting cells, T cells (CL) | Systemic (immune organs, mucosa) | Strong HLA‑B*51 association (~~6‑fold increased risk reported) with epistatic interaction with ERAP1 (reported OR ~4.6 for combined effect); multiple GWAS loci implicate IL10, IL23R–IL12RB2, STAT4 and NK/CCR loci. | Genetic strata inform mechanistic subtypes and suggest antigen‑processing (ERAP1/HLA) and cytokine pathway targets (IL‑23/IL‑17, JAK/STAT). | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Lin S., Front Immunol/2023, https://doi.org/10.3389/fimmu.2023.1206959 (lin2023advancesinpathogenesis pages 1-2) | | IFN / JAK‑STAT signatures & APC NF‑κB | IFNA/IFNB/IFNG, JAK1, STAT1/3, NFKB1 | Dendritic cells, monocytes/macrophages (CL) | Blood, skin, ocular tissues | Transcriptomic/interferome signals and enhanced NF‑κB activity in antigen‑presenting cells have been reported, supporting IFN and JAK‑STAT pathway involvement in BD immune activation. | JAK inhibitors and modulators of IFN/NF‑κB pathways are under study and show case/series evidence for refractory ocular/intestine/vascular BD. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Pu Y., Sci Rep/2025, https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9); Lin S., Front Immunol/2023, https://doi.org/10.3389/fimmu.2023.1206959 (lin2023advancesinpathogenesis pages 1-2) | | Microbiome & metabolome (oral / gut; intestinal BD) | Microbial taxa shifts (no single HGNC) | Mucosal immune cells, MAIT/γδ T cells (CL) | Oral cavity, gut (UBERON) | Studies report oral/gut dysbiosis signatures linked to BD flares and intestinal BD; integrated microbiome–metabolome work highlights disease‑specific profiles distinguishing intestinal BD from IBD. | Microbiome‑based biomarkers and microbiota‑targeted therapies (diet, probiotics, FMT experimental) are emerging research directions. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Guan Y., J Neuroinflamm/2024, https://doi.org/10.1186/s12974-024-03123-6 (guan2024decodingbehcet’suveitis pages 1-2); Pu Y., Sci Rep/2025, https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9) | | Organ phenotype — Oral / Genital ulcers | IL1B, TNF, NE (ELANE) | Neutrophils, keratinocytes, mucosal T cells (CL) | Oral & genital mucosa (UBERON) | Recurrent oral ulcers are the near‑universal presenting sign (>90% of patients); mucosal lesions show neutrophil‑predominant infiltration and leukocytoclastic vasculitis. | Local/topical care plus systemic anti‑inflammatory (colchicine, azathioprine) and targeted biologics (apremilast for mucocutaneous disease) reduce ulcer burden. | Lavalle S., Medicina/2024, https://doi.org/10.3390/medicina60040562 (lavalle2024behçet’sdiseasepathogenesis pages 10-11); Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2) | | Organ phenotype — Uveitis (ocular BD) | IL17A, IFNG, TNF, RORC | CD4+/CD8+ T cells, macrophages, retinal endothelium (CL) | Uveal tract, retina (UBERON) | Behçet uveitis affects >2/3 of BD patients and is vision‑threatening; one review estimates ~20.4% of affected eyes may become blind from recurrent episodes. | Rapid immunosuppression and biologics (anti‑TNF agents; IL‑6/IL‑17 blockers; increasing evidence for JAK inhibitors) improve outcomes and are used for refractory cases. | Guan Y., J Neuroinflamm/2024, https://doi.org/10.1186/s12974-024-03123-6 (guan2024decodingbehcet’suveitis pages 1-2); Lin S., Front Immunol/2023, https://doi.org/10.3389/fimmu.2023.1206959 (lin2023advancesinpathogenesis pages 1-2); Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2) | | Organ phenotype — Vascular / Intestinal / Neurologic BD | Procoagulant factors, IL1B, IFNs | Endothelium, monocytes, neutrophils, CNS glia (CL) | Large/small vessels, ileocecal gut, CNS (UBERON) | Vascular BD shows venous/arterial thrombosis and aneurysm risk; intestinal BD often targets ileocecal region with neutrophil/lymphocyte infiltrates; neuro‑BD shows perivascular cuffing—linking immune activation to organ damage. | Organ‑specific immunosuppression (anti‑TNF, anti‑IL‑1/IL‑6, JAK inhibitors), surgical approaches for aneurysms/intestinal complications; therapeutic choice informed by phenotype and molecular signatures. | Saadoun D., NEJM/2024, https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2); Shimizu J., Front Med/2023, https://doi.org/10.3389/fmed.2023.1055753 (shimizu2023innateimmuneresponses pages 10-11); Lavalle S., Medicina/2024, https://doi.org/10.3390/medicina60040562 (lavalle2024behçet’sdiseasepathogenesis pages 10-11) |

Table: A compact evidence table summarizing major molecular/cellular mechanisms, affected cell types and tissues, representative quantitative findings, therapeutic implications, and primary 2023–2025 sources (selected evidence IDs). This supports linking mechanistic biology to organ phenotypes and current targeted therapies (saadoun2024behçetssyndrome. pages 1-2).

1) Core pathophysiology - Innate immunity and NETs: Neutrophils in BD are primed to generate ROS and form NETs, promoting endothelial injury, perivascular inflammation, and a procoagulant milieu; lesions often show leukocytoclastic vasculitis and microthrombi (https://doi.org/10.1056/NEJMra2305712; 2024) (saadoun2024behçetssyndrome. pages 1-2). Reviews of innate mechanisms corroborate NET-linked macrophage activation and neutrophilic panniculitis/vasculitis in skin and mucosa (https://doi.org/10.3389/fmed.2023.1055753; 2023) (shimizu2023innateimmuneresponses pages 10-11). - Adaptive immunity: Th1 (IFN-γ/TNF-α) and Th17 (IL‑17/IL‑23) pathways are upregulated relative to Treg control; multi-omic integration emphasizes Th1/Th17 hyperactivity as the dominant molecular signature (https://doi.org/10.1038/s41598-025-87130-4; 2025) (pu2025integratedanalysisof pages 8-9). Ocular BD literature highlights Th1/Th17 and Treg imbalance in uveitis pathogenesis (https://doi.org/10.1186/s12974-024-03123-6; 2024; https://doi.org/10.3389/fimmu.2023.1206959; 2023) (guan2024decodingbehcet’suveitis pages 1-2, lin2023advancesinpathogenesis pages 1-2). - Endothelial dysfunction and vasculitis biology: Endothelial activation, perivascular leukocyte infiltration, and microthrombi underpin the variable-vessel vasculitis phenotype; haemostatic system activation and oxidative stress emerge in integrated analyses (https://doi.org/10.1056/NEJMra2305712; 2024; https://doi.org/10.1038/s41598-025-87130-4; 2025) (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9). - Genetic architecture and antigen processing: HLA‑B*51 confers major risk (reported ~6-fold) with a notable epistatic interaction with ERAP1 altering peptide trimming and HLA-I immunopeptidomes; non‑HLA loci include IL23R–IL12RB2, IL10, STAT4, CCR1/KLRC4, MICA that converge on Th1/Th17 and innate cell pathways (https://doi.org/10.1056/NEJMra2305712; 2024; https://doi.org/10.3389/fimmu.2023.1206959; 2023) (saadoun2024behçetssyndrome. pages 1-2, lin2023advancesinpathogenesis pages 1-2). - Interferon/JAK–STAT and NF‑κB signatures: Transcriptomic/interferome signals and APC NF‑κB activation have been reported in BD, consistent with heightened cytokine and co‑stimulatory signaling; these signatures motivate trials of JAK inhibition and anti‑cytokine therapies (https://doi.org/10.1056/NEJMra2305712; 2024; https://doi.org/10.1038/s41598-025-87130-4; 2025) (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9). - Microbiome/metabolome: Oral and gut dysbiosis are implicated as triggers, with intestinal BD showing disease‑specific microbial and metabolic profiles distinct from UC/controls in integrative studies; BD shares reduction in SCFA producers with IBD (NEJM 2024 summary; ocular BD review; integrated omics) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2, pu2025integratedanalysisof pages 8-9).

2) Key molecular players - Genes/proteins (HGNC): HLA‑B (HLA‑B*51), ERAP1, IL10, IL23R, IL12RB2, STAT4, CCR1, KLRC4, MICA; cytokines: TNF (TNF), IFNG (IFN‑γ), IL17A, IL23A/IL12B; signaling: JAK1/JAK3/STAT3/STAT1; innate mediators: MPO, ELANE (neutrophil elastase), PADI4; transcription factors: NFKB1‑RELA (p50/p65), RORC (RORγt) (https://doi.org/10.1056/NEJMra2305712; 2024; https://doi.org/10.3389/fimmu.2023.1206959; 2023; https://doi.org/10.1186/s12974-024-03123-6; 2024) (saadoun2024behçetssyndrome. pages 1-2, lin2023advancesinpathogenesis pages 1-2, guan2024decodingbehcet’suveitis pages 1-2). - Chemical entities (CHEBI): TNF inhibitors (infliximab, adalimumab), PDE4 inhibitor apremilast, IL‑12/23 inhibitor, IL‑17 inhibitors, JAK inhibitors; anti‑IL‑1 agents used in selected phenotypes (https://doi.org/10.3390/medicina60040562; 2024) (lavalle2024behçet’sdiseasepathogenesis pages 10-11). - Cell types (CL): Neutrophils (NETosis), monocytes/macrophages and dendritic cells (APC activation), CD4+ Th1/Th17 and Tregs, CD8+ Tc17, NK cells (KLRC4 pathway) (saadoun2024behçetssyndrome. pages 1-2, shimizu2023innateimmuneresponses pages 2-4). - Anatomical locations (UBERON): Oral/genital mucosa, skin, uveal tract/retina, systemic vasculature (veins/arteries), ileocecal intestine, CNS (parenchymal and vascular neuro‑BD) (saadoun2024behçetssyndrome. pages 1-2, shimizu2023innateimmuneresponses pages 2-4).

3) Disrupted biological processes (candidate GO terms) - Positive regulation of neutrophil activation and NET formation; response to reactive oxygen species; leukocyte adhesion to endothelium; cytokine-mediated signaling via JAK–STAT; NF‑κB signaling; Th17 cell differentiation; regulation of Treg-mediated tolerance; antigen processing and presentation via MHC class I (ERAP1/HLA‑B*51 axis); type I/II interferon signaling; regulation of coagulation and platelet activation (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9, lin2023advancesinpathogenesis pages 1-2).

4) Cellular components (GO-CC mapping) - Neutrophil granules and extracellular region (NETs); plasma membrane of endothelial cells (adhesion molecules); MHC class I peptide-loading complex in ER (ERAP1); cytosol/nucleus for NF‑κB and STAT transcriptional complexes; extracellular space (cytokines/chemokines) (saadoun2024behçetssyndrome. pages 1-2, lin2023advancesinpathogenesis pages 1-2).

5) Disease progression (sequence of events) - Triggering (microbial dysbiosis, mucosal injury, environmental stimuli) in genetically susceptible hosts → innate activation with neutrophil priming, ROS and NETs → endothelial activation/leukocytoclastic vasculitis and microthrombi → antigen presentation bias (HLA‑B*51/ERAP1) and APC NF‑κB upregulation → Th1/Th17 polarization with insufficient Treg control, with possible Tc17 involvement → organ-specific inflammation: oral/genital ulcers, ocular uveitis with retinal vasculitis, vascular thrombosis/aneurysm, ileocecal ulcers, and neuroinflammation (https://doi.org/10.1056/NEJMra2305712; 2024; ocular/innate reviews) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2, shimizu2023innateimmuneresponses pages 10-11).

6) Phenotypic manifestations and mechanistic links - Mucocutaneous: recurrent oral (>90%) and genital ulcers with neutrophil‑predominant infiltrates and small‑vessel vasculitis; linked to NET/IL‑1/TNF axes and barrier dysbiosis (https://doi.org/10.3390/medicina60040562; 2024; NEJM 2024) (lavalle2024behçet’sdiseasepathogenesis pages 10-11, saadoun2024behçetssyndrome. pages 1-2). - Ocular: bilateral, recurrent, non‑granulomatous uveitis with retinal vasculitis; Th1/Th17 and endothelial activation dominate; cumulative blindness risk is substantial without targeted therapy (https://doi.org/10.1186/s12974-024-03123-6; 2024) (guan2024decodingbehcet’suveitis pages 1-2). - Vascular: venous thrombosis and arterial aneurysms result from endothelial injury, neutrophil/NET-driven thrombogenicity, and cytokine activation (NEJM 2024) (saadoun2024behçetssyndrome. pages 1-2). - Intestinal BD: ileocecal ulcers with neutrophil/lymphocyte infiltrates; microbiome–metabolome profiles differ from UC/controls but share SCFA depletion, implicating barrier and innate pathways (integrated omics and reviews) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2, pu2025integratedanalysisof pages 8-9). - Neurologic BD: perivascular cuffing and inflammatory infiltrates suggest vasculitic and parenchymal mechanisms downstream of Th1/Th17 and innate activation (innate review; NEJM 2024) (shimizu2023innateimmuneresponses pages 10-11, saadoun2024behçetssyndrome. pages 1-2).

Recent developments and latest research (priority 2023–2024) - Consolidation of BD as a variable-vessel vasculitis with combined autoinflammatory/autoimmune features, with quantitative synthesis of genetic architecture (HLA‑B*51–ERAP1 epistasis) and Th1/Th17/NETs mechanisms in NEJM 2024 review (https://doi.org/10.1056/NEJMra2305712; 2024) (saadoun2024behçetssyndrome. pages 1-2). - Ocular BD reviews (2023–2024) emphasize Th1/Th17 dominance, Treg dysfunction, and new targets including JAK inhibition and Th17/Treg rebalancing (https://doi.org/10.3389/fimmu.2023.1206959; 2023; https://doi.org/10.1186/s12974-024-03123-6; 2024) (lin2023advancesinpathogenesis pages 1-2, guan2024decodingbehcet’suveitis pages 1-2). - Integrated multi‑omics (2025; data collected 2024) identify Th1/Th17 hyperactivity, enhanced neutrophil chemotaxis, endothelial injury, coagulation activation, and oxidative stress as central molecular programs (https://doi.org/10.1038/s41598-025-87130-4; 2025) (pu2025integratedanalysisof pages 8-9).

Current applications and real-world implementations - Organ‑tailored therapy grounded in mechanisms: mucocutaneous disease often responds to colchicine, azathioprine, PDE4 inhibition (apremilast), while sight‑threatening uveitis and major organ involvement utilize anti‑TNF agents; IL‑1/IL‑6, IL‑12/23 or IL‑17 blockade and JAK inhibitors are used in refractory cases in practice and studies (https://doi.org/10.3390/medicina60040562; 2024; NEJM 2024) (lavalle2024behçet’sdiseasepathogenesis pages 10-11, saadoun2024behçetssyndrome. pages 1-2).

Expert opinions and consensus - Authoritative reviews recommend a phenotype‑driven, early biologic approach for ocular and vascular disease, with escalation to targeted cytokine/JAK pathways for refractory inflammation; they stress genetic–immunologic heterogeneity (NEJM 2024; ocular/innate reviews 2023–2024) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2, shimizu2023innateimmuneresponses pages 10-11).

Relevant statistics and data (selected) - Epidemiology: prevalence varies widely by geography (e.g., Turkey up to ~420 per 100,000) (NEJM 2024) (saadoun2024behçetssyndrome. pages 1-2). - Genetics: HLA‑B*51 association (approximate ~6× risk) and ERAP1 epistasis reported with odds ratio ~4.6 in combined analyses (NEJM 2024) (saadoun2024behçetssyndrome. pages 1-2). - Ocular outcomes: BD uveitis occurs in >2/3 of patients; recurrent attacks can result in blindness in a substantial fraction of affected eyes without effective therapy (J Neuroinflammation 2024) (guan2024decodingbehcet’suveitis pages 1-2).

Ontology-annotated knowledge elements - Genes/proteins (HGNC): HLA‑B, ERAP1, IL10, IL23R, IL12RB2, STAT4, CCR1, KLRC4, MICA; cytokines TNF, IFNG, IL17A; signaling JAK1, STAT1/3, NFKB1/RELA; NET enzymes MPO, ELANE, PADI4 (saadoun2024behçetssyndrome. pages 1-2, lin2023advancesinpathogenesis pages 1-2, guan2024decodingbehcet’suveitis pages 1-2). - GO Biological Processes: neutrophil activation and extracellular trap formation; antigen processing and presentation via MHC class I; JAK–STAT cascade; regulation of NF‑κB transcription factor activity; Th17 cell differentiation; negative regulation of immune response by Treg; response to type I/II interferon; regulation of blood coagulation (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9). - GO Cellular Components: ER lumen/peptide-loading complex (ERAP1); extracellular region (NETs/cytokines); nucleus (NF‑κB/STAT complexes); plasma membrane (adhesion molecules) (lin2023advancesinpathogenesis pages 1-2, saadoun2024behçetssyndrome. pages 1-2). - Phenotype associations (HP): HP:0011107 Recurrent oral ulcers; HP:0001112 Uveitis; HP:0002632 Deep venous thrombosis; HP:0012387 Arterial aneurysm; HP:0002589 Abdominal pain/ileocecal ulcer; HP:0001287 Encephalopathy (neuro‑Behçet) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2, shimizu2023innateimmuneresponses pages 2-4). - Cell types (CL): CL:0000096 Neutrophil; CL:0000545 Dendritic cell; CL:0000236 Monocyte; CL:0000911 CD4+ T cell (Th1/Th17/Treg); CL:0000905 CD8+ T cell; CL:0000623 Endothelial cell (saadoun2024behçetssyndrome. pages 1-2, shimizu2023innateimmuneresponses pages 10-11). - Anatomical locations (UBERON): UBERON:0001836 Oral mucosa; UBERON:0000066 Skin; UBERON:0001772 Uvea; UBERON:0002390 Retina; UBERON:0002405 Vein; UBERON:0001987 Artery; UBERON:0002114 Small intestine (ileum/ileocecal); UBERON:0000955 Brain (saadoun2024behçetssyndrome. pages 1-2, shimizu2023innateimmuneresponses pages 2-4). - Chemical entities (CHEBI): apremilast (PDE4 inhibitor), infliximab/adalimumab (anti‑TNF), ustekinumab (anti‑IL‑12/23), secukinumab (anti‑IL‑17A), JAK inhibitors (e.g., tofacitinib/baricitinib/upadacitinib), canakinumab/anakinra (anti‑IL‑1)—mechanistically aligned classes (lavalle2024behçet’sdiseasepathogenesis pages 10-11, saadoun2024behçetssyndrome. pages 1-2).

Key evidence items (PMIDs/DOIs, dates, URLs) - Saadoun D, Bodaghi B, Cacoub P. Behçet’s syndrome. NEJM. Feb 15, 2024. DOI: 10.1056/NEJMra2305712. https://doi.org/10.1056/NEJMra2305712 (saadoun2024behçetssyndrome. pages 1-2). - Lin S et al. Advances in pathogenesis and treatment of ocular involvement in BD. Front Immunol. Sep 29, 2023. DOI: 10.3389/fimmu.2023.1206959. https://doi.org/10.3389/fimmu.2023.1206959 (lin2023advancesinpathogenesis pages 1-2). - Guan Y et al. Decoding Behçet’s uveitis. J Neuroinflammation. May 2024. DOI: 10.1186/s12974-024-03123-6. https://doi.org/10.1186/s12974-024-03123-6 (guan2024decodingbehcet’suveitis pages 1-2). - Shimizu J et al. Innate immune responses in BD and RP. Front Med. Jun 2023. DOI: 10.3389/fmed.2023.1055753. https://doi.org/10.3389/fmed.2023.1055753 (shimizu2023innateimmuneresponses pages 10-11). - Lavalle S et al. Behçet’s disease: pathogenesis, clinical features, and treatment. Medicina. Mar 2024. DOI: 10.3390/medicina60040562. https://doi.org/10.3390/medicina60040562 (lavalle2024behçet’sdiseasepathogenesis pages 10-11, lavalle2024behçet’sdiseasepathogenesis pages 9-10). - Pu Y et al. Integrated analysis of genetic, proteinic, and metabolomic alterations in BD. Sci Rep. Jan 2025 (data collected in 2024). DOI: 10.1038/s41598-025-87130-4. https://doi.org/10.1038/s41598-025-87130-4 (pu2025integratedanalysisof pages 8-9).

Direct supporting statements (quotes) - “Pathogenesis is viewed as genetically predisposed hosts exposed to environmental triggers … alterations of gut/salivary mucosal flora. Genetics: strong HLA‑B*51 association … loci include genes linked to Th1/Th17 polarization … and IL10. Immune mechanisms: … Th1 … Th17 … diminished regulatory T‑cell activity, and neutrophil hyperactivation.” (NEJM 2024) (saadoun2024behçetssyndrome. pages 1-2). - “Modules of antigen-presenting cells were associated with BS … Th17 cells … activation of the NF‑κB pathway … IL‑17‑associated pathways … IL‑17‑producing CD8+ T cells (Tc17) may play a critical role in BS.” (Ocular/immune system reviews; summarized) (lin2023advancesinpathogenesis pages 1-2, guan2024decodingbehcet’suveitis pages 1-2).

Mechanism-to-therapy mapping (applications) - NETs/endothelial axis → anti‑TNF for ocular/vascular disease; consideration of anti‑IL‑1/IL‑6 in selected phenotypes (saadoun2024behçetssyndrome. pages 1-2, lavalle2024behçet’sdiseasepathogenesis pages 10-11). - Th17/Tc17 axis → anti‑IL‑17 or anti‑IL‑12/23; JAK inhibition as pathway‑level modulation (guan2024decodingbehcet’suveitis pages 1-2, lin2023advancesinpathogenesis pages 1-2). - APC NF‑κB and IFN/JAK–STAT signatures → JAK inhibitors in refractory mucocutaneous/ocular/intestinal disease; phenotype‑guided escalation (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9).

Limitations and open questions - The precise microbiome causal pathways and antigenic drivers remain incompletely defined; interferome and cell‑type–resolved datasets are expanding but heterogeneous. Prospective mechanotype‑guided trials are needed to align genetic/immune endotypes with therapy selection (saadoun2024behçetssyndrome. pages 1-2, pu2025integratedanalysisof pages 8-9).

Overall synthesis BD pathophysiology reflects a genetically primed, mucosa‑initiated systemic vasculitis in which neutrophil/NET–endothelial circuits, Th1/Th17 skewing (with possible Tc17), and APC NF‑κB/IFN–JAK–STAT signaling cooperate to produce relapsing inflammation across mucocutaneous, ocular, vascular, intestinal, and neurologic sites. Current real‑world practice increasingly targets these axes with anti‑TNF, IL‑17/IL‑12‑23, PDE4, and JAK inhibition in phenotype‑guided regimens (https://doi.org/10.1056/NEJMra2305712; 2024; https://doi.org/10.1186/s12974-024-03123-6; 2024) (saadoun2024behçetssyndrome. pages 1-2, guan2024decodingbehcet’suveitis pages 1-2).

References

  1. (saadoun2024behçetssyndrome. pages 1-2): David Saadoun, Bahram Bodaghi, and Patrice Cacoub. Behçet's syndrome. The New England journal of medicine, 390 7:640-651, Feb 2024. URL: https://doi.org/10.1056/nejmra2305712, doi:10.1056/nejmra2305712. This article has 78 citations and is from a highest quality peer-reviewed journal.

  2. (guan2024decodingbehcet’suveitis pages 1-2): Yuxuan Guan, Fuzhen Li, Na Li, and Peizeng Yang. Decoding behcet’s uveitis: an in-depth review of pathogenesis and therapeutic advances. Journal of Neuroinflammation, May 2024. URL: https://doi.org/10.1186/s12974-024-03123-6, doi:10.1186/s12974-024-03123-6. This article has 19 citations and is from a peer-reviewed journal.

  3. (lin2023advancesinpathogenesis pages 1-2): Suibin Lin, Zhirong Xu, Zhiming Lin, Baozhao Xie, and Junmei Feng. Advances in pathogenesis and treatment of ocular involvement in behcet’s disease. Frontiers in Immunology, Sep 2023. URL: https://doi.org/10.3389/fimmu.2023.1206959, doi:10.3389/fimmu.2023.1206959. This article has 7 citations and is from a peer-reviewed journal.

  4. (pu2025integratedanalysisof pages 8-9): Yanlin Pu, Jing Liang, Yao Wang, Wanyun Zhang, Chuiren Zhou, Ju Shao, Jin Hu, Minghui Chen, Yunjie Shi, Yongdan Mao, and Zhijun Chen. Integrated analysis of genetic, proteinic, and metabolomic alterations in behcet’s disease. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-025-87130-4, doi:10.1038/s41598-025-87130-4. This article has 4 citations and is from a peer-reviewed journal.

  5. (shimizu2023innateimmuneresponses pages 10-11): Jun Shimizu, Masanori A. Murayama, Yoshihisa Mizukami, Nagisa Arimitsu, Kenji Takai, and Yoshishige Miyabe. Innate immune responses in behçet disease and relapsing polychondritis. Frontiers in Medicine, Jun 2023. URL: https://doi.org/10.3389/fmed.2023.1055753, doi:10.3389/fmed.2023.1055753. This article has 13 citations and is from a poor quality or predatory journal.

  6. (lavalle2024behçet’sdiseasepathogenesis pages 10-11): Salvatore Lavalle, Sebastiano Caruso, Roberta Foti, Caterina Gagliano, Salvatore Cocuzza, Luigi La Via, Federica Maria Parisi, Christian Calvo-Henriquez, and Antonino Maniaci. Behçet’s disease, pathogenesis, clinical features, and treatment approaches: a comprehensive review. Medicina, 60:562, Mar 2024. URL: https://doi.org/10.3390/medicina60040562, doi:10.3390/medicina60040562. This article has 55 citations and is from a poor quality or predatory journal.

  7. (shimizu2023innateimmuneresponses pages 2-4): Jun Shimizu, Masanori A. Murayama, Yoshihisa Mizukami, Nagisa Arimitsu, Kenji Takai, and Yoshishige Miyabe. Innate immune responses in behçet disease and relapsing polychondritis. Frontiers in Medicine, Jun 2023. URL: https://doi.org/10.3389/fmed.2023.1055753, doi:10.3389/fmed.2023.1055753. This article has 13 citations and is from a poor quality or predatory journal.

  8. (lavalle2024behçet’sdiseasepathogenesis pages 9-10): Salvatore Lavalle, Sebastiano Caruso, Roberta Foti, Caterina Gagliano, Salvatore Cocuzza, Luigi La Via, Federica Maria Parisi, Christian Calvo-Henriquez, and Antonino Maniaci. Behçet’s disease, pathogenesis, clinical features, and treatment approaches: a comprehensive review. Medicina, 60:562, Mar 2024. URL: https://doi.org/10.3390/medicina60040562, doi:10.3390/medicina60040562. This article has 55 citations and is from a poor quality or predatory journal.